Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Wagner U, Jackisch C, Meier W, Schmalfeldt B, Stähle A, Gropp M, Sehouli J, Lück H, Loibl S, Huober J, Pfisterer J, du Bois A, AGO Ovarian Cancer Study Group. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic oncology 2007; 105:132-7.
01.04.2007
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
01.04.2007
Gynecologic oncology 2007; 105:132-7
Wagner Uwe, Jackisch Christian, Meier Werner, Schmalfeldt Barbara, Stähle Anne, Gropp Martina, Sehouli Jalid, Lück Hans-Joachim, Loibl Sybille, Huober Jens, Pfisterer Jacobus, du Bois Andreas, AGO Ovarian Cancer Study Group
Weiter
